RECRUITING

Molecular Epidemiology of Biliary Tree Cancers

Study Overview

This clinical trial focuses on testing the efficacy of different digital interventions to promote re-engagement in cancer-related long-term follow-up care for adolescent and young adult (AYA) survivors of childhood cancer.

Description

This study is to learn if certain risk factors (environmental, viral, behavioral, medical, and dietary), tumor markers, and genetic changes can predict the development and outcome of biliary tree cancers. Establishing biomarkers models from patients may help doctors to further understand how biliary tree cancer is affected by different treatments, and why some people's cancer responds differently than others.

Official Title

Molecular Epidemiology of Biliary Tree Cancers

Quick Facts

Study Start:2017-09-25
Study Completion:2027-02-02
Study Type:Not specified
Phase:Not Applicable
Enrollment:Not specified
Status:RECRUITING

Study ID

NCT05179486

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Ages Eligible for Study:Not specified
Sexes Eligible for Study:ALL
Accepts Healthy Volunteers:Not specified
Standard Ages:CHILD, ADULT, OLDER_ADULT
Inclusion CriteriaExclusion Criteria
  1. * Pathologically or radiologically confirmed diagnosis of CGC or GBC
  2. * With or without prior radiation or chemotherapy
  3. * All United States of America (USA) and non USA residents
  4. * No age, gender, or racial restriction
  5. * Healthy control with no current or history of cancer
  6. * Healthy controls are USA and non USA residents
  7. * Healthy controls are matched to the cases in age (5 years), gender, and race
  8. * Healthy controls are friends and spouses of patients with other than gastro-intestinal (GI) cancers
  9. * Chronic Liver Disease (CLD) controls with no current or history of cancer
  10. * CLD controls are USA and non USA residents
  11. * CLD controls are frequency matched to CGC cases by age (5 years), gender, and race
  12. * CLD controls are patients are diagnosed with or without liver biopsy (core or fine needle aspiration)
  13. * CLD controls must not have evidence liver cancer diagnosis by computed tomography (CT) or magnetic resonance imaging (MRI)
  1. * None

Contacts and Locations

Study Contact

Manal M Hassan
CONTACT
713-794-5452
mhassan@mdanderson.org

Principal Investigator

Manal M Hassan
PRINCIPAL_INVESTIGATOR
M.D. Anderson Cancer Center

Study Locations (Sites)

M D Anderson Cancer Center
Houston, Texas, 77030
United States

Collaborators and Investigators

Sponsor: M.D. Anderson Cancer Center

  • Manal M Hassan, PRINCIPAL_INVESTIGATOR, M.D. Anderson Cancer Center

Study Record Dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Registration Dates

Study Start Date2017-09-25
Study Completion Date2027-02-02

Study Record Updates

Study Start Date2017-09-25
Study Completion Date2027-02-02

Terms related to this study

Additional Relevant MeSH Terms

  • Cholangiocarcinoma
  • Malignant Digestive System Neoplasm